Intellectia LogoIntellectia
Product
Resources
Markets
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. NEO
stocks logo

NEO

-
Add to WatchlistAdvanced Chart
$
0.000
0(0.000%)1D
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q1
FY2025Q2
FY2025Q3
183.03M
+11.26%
-0.010
-50%
192.63M
+14.78%
0.025
-15.4%
200.87M
+16.79%
0.054
+7.7%
Estimates Revision
The market is revising Upward the revenue expectations for NeoGenomics, Inc. (NEO) for FY2025, with the revenue forecasts being adjusted by 0.99% over the past three months. During the same period, the stock price has changed by -30.79%.
Revenue Estimates for FY2025
Revise Upward
up Image
+0.99%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-8.82%
In Past 3 Month
Stock Price
Go Down
down Image
-30.79%
In Past 3 Month
11 Analyst Rating
up Image0
Wall Street analysts forecast NEO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NEO is 13.19 USD with a low forecast of 8.50 USD and a high forecast of 26.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Buy
4 Hold
0 Sell
Moderate Buy
up Image0
Current: 6.630
sliders
Low
8.50
Averages
13.19
High
26.00
up Image0
Current: 6.630
sliders
Low
8.50
Averages
13.19
High
26.00
Craig-Hallum
Buy
initiated
$15
2025-06-19
Reason
Craig-Hallum
Price Target
$15
2025-06-19
initiated
Buy
Reason
As previously reported, Craig-Hallum initiated coverage of Adaptive Biotechnologies (ADPT) with a Buy rating and $15 price target. The firm notes Adaptive is essentially the only player in the $1.8B heme MRD market, with prospects for sustainable 20%-plus growth, multiple near-term growth drivers, an outlook for substantial margin expansion, turning EBITDA break-even in their core business, and a track record of beating estimates. Near-term catalysts include increased coverage and payor reimbursement rates, adoption of MRD in clinical trials, EMR integrations, a strategic partnership with NeoGenomics (NEO), and the transition to a new test platform that will boost gross margins, Craig-Hallum adds.
Guggenheim
Subbu Nambi
Neutral
initiated
2025-05-15
Reason
Guggenheim
Subbu Nambi
Price Target
2025-05-15
initiated
Neutral
Reason
Guggenheim analyst Subbu Nambi initiated coverage of NeoGenomics with a Neutral rating.
Guggenheim
Neutral
initiated
2025-05-15
Reason
Guggenheim
Price Target
2025-05-15
initiated
Neutral
Reason
Goldman Sachs
Matthew Sykes
Strong Buy
Maintains
$17 → $15
2025-04-17
Reason
Goldman Sachs
Matthew Sykes
Price Target
$17 → $15
2025-04-17
Maintains
Strong Buy
Reason
Piper Sandler
David Westenberg
Buy
Maintains
$21 → $18
2025-02-26
Reason
Piper Sandler
David Westenberg
Price Target
$21 → $18
2025-02-26
Maintains
Buy
Reason
Piper Sandler lowered the firm's price target on NeoGenomics to $18 from $21 following quarterly results. The firm keeps an Overweight rating on the shares.
Needham
Mike Matson
Strong Buy
Maintains
$19 → $18
2025-02-19
Reason
Needham
Mike Matson
Price Target
$19 → $18
2025-02-19
Maintains
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Neogenomics Inc (NEO.O) is 37.37, compared to its 5-year average forward P/E of 36.24. For a more detailed relative valuation and DCF analysis to assess Neogenomics Inc 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
36.24
Current PE
37.37
Overvalued PE
247.18
Undervalued PE
-174.70

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
129.70
Current EV/EBITDA
19.25
Overvalued EV/EBITDA
1445.26
Undervalued EV/EBITDA
-1185.87

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average PS
5.00
Current PS
1.16
Overvalued PS
8.50
Undervalued PS
1.51

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought

NEO News & Events

Events Timeline

(ET)
2025-04-29
07:35:06
NeoGenomics raises FY25 revenue view to $747M-$759M from $735M-$745M
select
2025-04-29
07:33:12
NeoGenomics reports Q1 EPS 0c, consensus (1c)
select
2025-04-07 (ET)
2025-04-07
07:06:39
NeoGenomics completes acquisition of Pathline
select
Sign Up For More Events
Sign Up For More Events

News

Preview
7.0
07-08PRnewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zeo Energy Corp. - ZEO

  • Investigation Announcement: Pomerantz LLP is investigating potential securities fraud and unlawful business practices involving Zeo Energy Corp, following a notice from Nasdaq regarding the company's non-compliance with filing requirements.

  • Stock Price Impact: After the announcement of the investigation and the compliance issue, Zeo's stock price dropped by nearly 10%, closing at $3.09 per share.

Preview
7.0
07-06Globenewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zeo Energy Corp. - ZEO

  • Investigation into Zeo Energy Corp: Pomerantz LLP is investigating potential securities fraud and unlawful business practices by Zeo Energy Corp and its officers, following the company's failure to file a required quarterly report with the SEC.

  • Impact on Stock Price: After the announcement of non-compliance with Nasdaq listing requirements, Zeo's stock price dropped nearly 10%, closing at $3.09 per share.

Preview
3.0
07-01Newsfilter
NeoGenomics to Report Second Quarter 2025 Financial Results on July 29, 2025

  • Upcoming Financial Results Announcement: NeoGenomics, Inc. will report its second quarter 2025 financial results on July 29, 2025, with a conference call scheduled for 8:30 a.m. ET to discuss the results and recent highlights.

  • Company Overview: NeoGenomics is a leading cancer diagnostics company that provides comprehensive oncology-focused testing services to various healthcare professionals and institutions, operating accredited laboratories in the U.S. and the UK.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Neogenomics Inc (NEO) stock price today?

The current price of NEO is 6.63 USD — it has decreased -1.34 % in the last trading day.

arrow icon

What is Neogenomics Inc (NEO)'s business?

NeoGenomics, Inc. is a cancer diagnostics company specializing in cancer genetics testing and information services. The Company offers comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with diagnostic and predictive testing to help them diagnose and treat cancer. Its services include clinical cancer testing; interpretation and consultative services; molecular and NGS testing; comprehensive technical and professional services offering; clinical trials and research; validation laboratory services, and oncology data solutions. It operates a network of laboratories for full-service sample processing and analysis services throughout the United States and a full-service sample-processing laboratory in Cambridge, United Kingdom. Its testing services include Cytogenetics (karyotype analysis), Fluorescence In-Situ Hybridization (FISH), Flow cytometry, and others.

arrow icon

What is the price predicton of NEO Stock?

Wall Street analysts forecast NEO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NEO is 13.19 USD with a low forecast of 8.50 USD and a high forecast of 26.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Neogenomics Inc (NEO)'s revenue for the last quarter?

Neogenomics Inc revenue for the last quarter amounts to 168.04M USD, increased 7.55 % YoY.

arrow icon

What is Neogenomics Inc (NEO)'s earnings per share (EPS) for the last quarter?

Neogenomics Inc. EPS for the last quarter amounts to -0.20 USD, decreased -4.76 % YoY.

arrow icon

What changes have occurred in the market's expectations for Neogenomics Inc (NEO)'s fundamentals?

The market is revising Upward the revenue expectations for NeoGenomics, Inc. (NEO) for FY2025, with the revenue forecasts being adjusted by 0.99% over the past three months. During the same period, the stock price has changed by -30.79%.
arrow icon

How many employees does Neogenomics Inc (NEO). have?

Neogenomics Inc (NEO) has 2200 emplpoyees as of July 18 2025.

arrow icon

What is Neogenomics Inc (NEO) market cap?

Today NEO has the market capitalization of 864.83M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free